Abstract:Myelofibrosis (MF) is a chronic myeloid neoplasm characterized by myeloproliferation, bone marrow fibrosis, splenomegaly, and constitutional symptoms related to pro-inflammatory cytokine signaling. Biologically, MF is characterized by constitutive activation of JAK-STAT signaling; accordingly, JAK inhibitors have been rationally developed to treat MF. Following the initial approval of ruxolitinib in 2011, three additional agents have been approved: fedratinib, pacritinib, and momelotinib. As these therapies are non-curative, allogeneic stem cell transplantation remains a key treatment modality and patients with MF who are deemed candidates should be referred to a transplant center. This potentially curative but toxic approach is typically reserved for patients with higher-risk disease, and JAK inhibitors are recommended in the pre-transplant setting. JAK inhibitors have proven effective at managing splenomegaly and constitutional symptoms and should be started early in the disease course in patients presenting with these clinical manifestations; asymptomatic patients may initially be followed with close surveillance. Drug-related myelosuppression has been a challenge with initial JAK inhibitors, particularly in patients presenting with a cytopenic phenotype. However, newer agents, namely pacritinib and momelotinib, have proven more effective in this setting and are approved for patients with significant thrombocytopenia and anemia, respectively. Resistance or disease progression is clinically challenging and may be defined by several possible events, such as increasing splenomegaly or progression to accelerated or blast phase disease. However, with multiple JAK inhibitors now approved, sequencing of these agents appears poised to improve outcomes. Additionally, novel JAK inhibitors and JAK inhibitor-based combinations are in clinical development.

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis

Safety and Efficacy of Jaktinib in the Treatment of Janus Kinase Inhibitor‐naïve Patients with Myelofibrosis: Results of a Phase II Trial

0JAK Inhibitor Withdrawal Causes a Transient Proinflammatory Cascade: A Potential Mechanism for Major Adverse Cardiac Events

JAK Inhibitor Withdrawal Causes a Transient Proinflammatory Cascade: A Potential Mechanism for Major Adverse Cardiac Events

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

Emerging drug profile: JAK inhibitors

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms

Deregulation of the p19/CDK4/CDK6 axis in Jak2 V617F megakaryocytes accelerates the development of myelofibrosis

Amino Acid Residue E543 in Jak2 C618r is A Potential Therapeutic Target for Myeloproliferative Disorders Caused by Jak2 C618r Mutation

Effects of JAK2 V556F Mutation on the JAK2's Activity, Structural Stability and the Transformation of Ba/F3 Cells.

Janus kinase 2 inhibitors in myeloproliferative disorders

Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis

Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights

Loss of Pleckstrin-2 Reverts Lethality and Vascular Occlusions in JAK2V617F-positive Myeloproliferative Neoplasms

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

The Effects of R683S (G) Genetic Mutations on the JAK2 Activity, Structure and Stability.

Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F

Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.

SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis

New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms